A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group

Guido Torzilli, Jacques Belghiti, Norihiro Kokudo, Tadatoshi Takayama, Lorenzo Capussotti, Gennaro Nuzzo, Jean Nicolas Vauthey, Michael A. Choti, Eduardo De Santibanes, Matteo Donadon, Emanuela Morenghi, Masatoshi Makuuchi

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The aim of this study was to investigate in a retrospective setting the patients' profile and results of those undergoing surgery for hepatocellular carcinoma (HCC) in high-volume surgical centers throughout the world. BACKGROUND: Whether surgery for HCC is a suitable approach and for which subset of patients is still controversial. The EASL/AASLD (European Association for the Study of Liver Disease/American Association for the Study of Liver Disease) guidelines, based on the Barcelona Clinic Liver Cancer (BCLC) classification, leave little room for hepatic resection; inversely, other reports promote its wider application. METHODS: On the basis of the network "Hepatocellular Carcinoma: Eastern & Western Experiences," data for 2046 consecutive patients resected for HCC in 10 centers were collected. According to the BCLC classification, 1012 (50%) were BCLC 0-A, 737 (36%) BCLC B, and 297 (14%) BCLC C. Analysis of overall survival and disease-free survival and multivariate analysis of prognostic factors were performed. FINDINGS.: The 90-day mortality rate was 2.7%. Overall morbidity was 42%. After a median follow-up of 25 months (range, 1-209 months), the 1-, 3-, and 5-year overall survival rates were 95%, 80%, and 61% for BCLC 0-A; 88%, 71%, and 57% for BCLC B; and 76%, 49%, and 38% for BCLC C (P = 0.000). The 1-, 3-, and 5-year disease-free survival rates were as follows: 77%, 41%, and 21% for BCLC 0-A; 63%, 38%, and 27% for BCLC B; and 46%, 28%, and 18% for BCLC C (P = 0.000). The multivariate analysis identified bilirubin, cirrhosis, esophageal varices, tumor size, and macrovascular invasion to be statistical and independent prognostic factors for overall survival. CONCLUSIONS: This large multicentric survey shows that surgery is in current practice widely applied among patients with multinodular, large, and macrovascular invasive HCC, providing acceptable short- and long-term results and justifying an update of the EASL/AASLD therapeutic guidelines in this sense.

Original languageEnglish (US)
Pages (from-to)929-937
Number of pages9
JournalAnnals of Surgery
Volume257
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Liver Neoplasms
Tertiary Care Centers
Observational Studies
Liver Diseases
Hepatocellular Carcinoma
Survival Analysis
Disease-Free Survival
Multivariate Analysis
Survival Rate
Guidelines
Esophageal and Gastric Varices
Bilirubin
Fibrosis
Morbidity
Survival
Mortality

Keywords

  • Barcelona Clinic Liver Cancer classification
  • chronic hepatitis
  • hepatocellular carcinoma
  • liver cirrhosis
  • liver surgery
  • sorafenib

ASJC Scopus subject areas

  • Surgery

Cite this

A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers : Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. / Torzilli, Guido; Belghiti, Jacques; Kokudo, Norihiro; Takayama, Tadatoshi; Capussotti, Lorenzo; Nuzzo, Gennaro; Vauthey, Jean Nicolas; Choti, Michael A.; De Santibanes, Eduardo; Donadon, Matteo; Morenghi, Emanuela; Makuuchi, Masatoshi.

In: Annals of Surgery, Vol. 257, No. 5, 05.2013, p. 929-937.

Research output: Contribution to journalArticle

Torzilli, G, Belghiti, J, Kokudo, N, Takayama, T, Capussotti, L, Nuzzo, G, Vauthey, JN, Choti, MA, De Santibanes, E, Donadon, M, Morenghi, E & Makuuchi, M 2013, 'A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group', Annals of Surgery, vol. 257, no. 5, pp. 929-937. https://doi.org/10.1097/SLA.0b013e31828329b8
Torzilli, Guido ; Belghiti, Jacques ; Kokudo, Norihiro ; Takayama, Tadatoshi ; Capussotti, Lorenzo ; Nuzzo, Gennaro ; Vauthey, Jean Nicolas ; Choti, Michael A. ; De Santibanes, Eduardo ; Donadon, Matteo ; Morenghi, Emanuela ; Makuuchi, Masatoshi. / A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers : Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. In: Annals of Surgery. 2013 ; Vol. 257, No. 5. pp. 929-937.
@article{4ec3e79eb80b4ba2afda090ac8524fc4,
title = "A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group",
abstract = "OBJECTIVE: The aim of this study was to investigate in a retrospective setting the patients' profile and results of those undergoing surgery for hepatocellular carcinoma (HCC) in high-volume surgical centers throughout the world. BACKGROUND: Whether surgery for HCC is a suitable approach and for which subset of patients is still controversial. The EASL/AASLD (European Association for the Study of Liver Disease/American Association for the Study of Liver Disease) guidelines, based on the Barcelona Clinic Liver Cancer (BCLC) classification, leave little room for hepatic resection; inversely, other reports promote its wider application. METHODS: On the basis of the network {"}Hepatocellular Carcinoma: Eastern & Western Experiences,{"} data for 2046 consecutive patients resected for HCC in 10 centers were collected. According to the BCLC classification, 1012 (50{\%}) were BCLC 0-A, 737 (36{\%}) BCLC B, and 297 (14{\%}) BCLC C. Analysis of overall survival and disease-free survival and multivariate analysis of prognostic factors were performed. FINDINGS.: The 90-day mortality rate was 2.7{\%}. Overall morbidity was 42{\%}. After a median follow-up of 25 months (range, 1-209 months), the 1-, 3-, and 5-year overall survival rates were 95{\%}, 80{\%}, and 61{\%} for BCLC 0-A; 88{\%}, 71{\%}, and 57{\%} for BCLC B; and 76{\%}, 49{\%}, and 38{\%} for BCLC C (P = 0.000). The 1-, 3-, and 5-year disease-free survival rates were as follows: 77{\%}, 41{\%}, and 21{\%} for BCLC 0-A; 63{\%}, 38{\%}, and 27{\%} for BCLC B; and 46{\%}, 28{\%}, and 18{\%} for BCLC C (P = 0.000). The multivariate analysis identified bilirubin, cirrhosis, esophageal varices, tumor size, and macrovascular invasion to be statistical and independent prognostic factors for overall survival. CONCLUSIONS: This large multicentric survey shows that surgery is in current practice widely applied among patients with multinodular, large, and macrovascular invasive HCC, providing acceptable short- and long-term results and justifying an update of the EASL/AASLD therapeutic guidelines in this sense.",
keywords = "Barcelona Clinic Liver Cancer classification, chronic hepatitis, hepatocellular carcinoma, liver cirrhosis, liver surgery, sorafenib",
author = "Guido Torzilli and Jacques Belghiti and Norihiro Kokudo and Tadatoshi Takayama and Lorenzo Capussotti and Gennaro Nuzzo and Vauthey, {Jean Nicolas} and Choti, {Michael A.} and {De Santibanes}, Eduardo and Matteo Donadon and Emanuela Morenghi and Masatoshi Makuuchi",
year = "2013",
month = "5",
doi = "10.1097/SLA.0b013e31828329b8",
language = "English (US)",
volume = "257",
pages = "929--937",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers

T2 - Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group

AU - Torzilli, Guido

AU - Belghiti, Jacques

AU - Kokudo, Norihiro

AU - Takayama, Tadatoshi

AU - Capussotti, Lorenzo

AU - Nuzzo, Gennaro

AU - Vauthey, Jean Nicolas

AU - Choti, Michael A.

AU - De Santibanes, Eduardo

AU - Donadon, Matteo

AU - Morenghi, Emanuela

AU - Makuuchi, Masatoshi

PY - 2013/5

Y1 - 2013/5

N2 - OBJECTIVE: The aim of this study was to investigate in a retrospective setting the patients' profile and results of those undergoing surgery for hepatocellular carcinoma (HCC) in high-volume surgical centers throughout the world. BACKGROUND: Whether surgery for HCC is a suitable approach and for which subset of patients is still controversial. The EASL/AASLD (European Association for the Study of Liver Disease/American Association for the Study of Liver Disease) guidelines, based on the Barcelona Clinic Liver Cancer (BCLC) classification, leave little room for hepatic resection; inversely, other reports promote its wider application. METHODS: On the basis of the network "Hepatocellular Carcinoma: Eastern & Western Experiences," data for 2046 consecutive patients resected for HCC in 10 centers were collected. According to the BCLC classification, 1012 (50%) were BCLC 0-A, 737 (36%) BCLC B, and 297 (14%) BCLC C. Analysis of overall survival and disease-free survival and multivariate analysis of prognostic factors were performed. FINDINGS.: The 90-day mortality rate was 2.7%. Overall morbidity was 42%. After a median follow-up of 25 months (range, 1-209 months), the 1-, 3-, and 5-year overall survival rates were 95%, 80%, and 61% for BCLC 0-A; 88%, 71%, and 57% for BCLC B; and 76%, 49%, and 38% for BCLC C (P = 0.000). The 1-, 3-, and 5-year disease-free survival rates were as follows: 77%, 41%, and 21% for BCLC 0-A; 63%, 38%, and 27% for BCLC B; and 46%, 28%, and 18% for BCLC C (P = 0.000). The multivariate analysis identified bilirubin, cirrhosis, esophageal varices, tumor size, and macrovascular invasion to be statistical and independent prognostic factors for overall survival. CONCLUSIONS: This large multicentric survey shows that surgery is in current practice widely applied among patients with multinodular, large, and macrovascular invasive HCC, providing acceptable short- and long-term results and justifying an update of the EASL/AASLD therapeutic guidelines in this sense.

AB - OBJECTIVE: The aim of this study was to investigate in a retrospective setting the patients' profile and results of those undergoing surgery for hepatocellular carcinoma (HCC) in high-volume surgical centers throughout the world. BACKGROUND: Whether surgery for HCC is a suitable approach and for which subset of patients is still controversial. The EASL/AASLD (European Association for the Study of Liver Disease/American Association for the Study of Liver Disease) guidelines, based on the Barcelona Clinic Liver Cancer (BCLC) classification, leave little room for hepatic resection; inversely, other reports promote its wider application. METHODS: On the basis of the network "Hepatocellular Carcinoma: Eastern & Western Experiences," data for 2046 consecutive patients resected for HCC in 10 centers were collected. According to the BCLC classification, 1012 (50%) were BCLC 0-A, 737 (36%) BCLC B, and 297 (14%) BCLC C. Analysis of overall survival and disease-free survival and multivariate analysis of prognostic factors were performed. FINDINGS.: The 90-day mortality rate was 2.7%. Overall morbidity was 42%. After a median follow-up of 25 months (range, 1-209 months), the 1-, 3-, and 5-year overall survival rates were 95%, 80%, and 61% for BCLC 0-A; 88%, 71%, and 57% for BCLC B; and 76%, 49%, and 38% for BCLC C (P = 0.000). The 1-, 3-, and 5-year disease-free survival rates were as follows: 77%, 41%, and 21% for BCLC 0-A; 63%, 38%, and 27% for BCLC B; and 46%, 28%, and 18% for BCLC C (P = 0.000). The multivariate analysis identified bilirubin, cirrhosis, esophageal varices, tumor size, and macrovascular invasion to be statistical and independent prognostic factors for overall survival. CONCLUSIONS: This large multicentric survey shows that surgery is in current practice widely applied among patients with multinodular, large, and macrovascular invasive HCC, providing acceptable short- and long-term results and justifying an update of the EASL/AASLD therapeutic guidelines in this sense.

KW - Barcelona Clinic Liver Cancer classification

KW - chronic hepatitis

KW - hepatocellular carcinoma

KW - liver cirrhosis

KW - liver surgery

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84876287771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876287771&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31828329b8

DO - 10.1097/SLA.0b013e31828329b8

M3 - Article

C2 - 23426336

AN - SCOPUS:84876287771

VL - 257

SP - 929

EP - 937

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 5

ER -